No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Why the study?
Does ticagrelor pretreatment reduce the composite of all-cause mortality, MI, or stent thrombosis in patients with STEMI undergoing primary PCI?
Population
Patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention
Comparison
Ticagrelor pretreatment vs Ticagrelor given in the catheterization…
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Ticagrelor pretreatment was not associated with better outcomes in STEMI primary PCI; leaves open the need for randomized confirmation of optimal timing.
Structured PICO
Does ticagrelor pretreatment reduce the composite of all-cause mortality, MI, or stent thrombosis in patients with STEMI undergoing primary PCI?
P
Population
Patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)
I
Intervention
Ticagrelor pretreatment
C
Comparator
Ticagrelor given in the catheterization laboratory during PCI
O
Outcome
Composite end point of all-cause mortality or MI or stent thrombosis at 30 dayscomposite
Ticagrelor pretreatment does not improve 30-day clinical outcomes compared to administration in the catheterization laboratory in STEMI patients undergoing primary PCI.
Cite This Study
Koul et al. (2018) studied this question.